Integer Holding stock rating reiterated at Overweight by KeyBanc

Investing.com - KeyBanc has reiterated an Overweight rating on Integer Holding (NYSE:ITGR) with a price target of $145.00, following meetings with the company’s management team. The stock, currently trading near its 52-week low of $104.93, maintains a strong "Buy" consensus among analysts with targets ranging from $132 to $155.

The meetings included CEO Joe Dziedzic, COO and incoming CEO Payman Khales, CFO Diron Smith, and other executives. KeyBanc expressed confidence in Integer’s ability to meet its 2025 guidance and execute against long-term financial objectives.

Management addressed investor concerns regarding implied second-half versus first-half organic growth deceleration while maintaining confidence in the company’s 2025 outlook. Integer appears well-positioned to sustain its organic growth objective of "market plus at least 200 basis points," supported by multiple company-specific initiatives.

Integer continues to target longer-term operating income growth at twice the rate of sales growth, though KeyBanc noted the company does not expect to achieve this ambitious goal every year. The research firm highlighted this as part of Integer’s broader financial strategy.

Mergers and acquisitions remain central to Integer’s strategy, with management communicating a healthy pipeline of potential targets, according to KeyBanc’s report following the management meetings.

In other recent news, Integer Holdings reported its second-quarter 2025 results, showcasing a revenue increase of 11% organically to $476.0 million compared to the same period last year. The company’s adjusted earnings per share rose by 19% to $1.55, surpassing the previous year’s second-quarter figures. Despite these positive results, the stock experienced a decline, attributed to broader market concerns about future growth and competitive pressures. Analysts have shown confidence in the company’s performance, with Benchmark reaffirming a Buy rating and maintaining a $140.00 price target. Citi also reiterated its Buy rating and the same price target, highlighting strong revenue performance, particularly in the Cardio & Vascular segment, which saw a 17.6% year-over-year organic growth. The CRM & Neuromodulation segment also reported a modest 2.3% increase year-over-year. These developments indicate sustained growth in key business areas, which analysts from Benchmark and Citi have recognized.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.